Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Gliosarcoma 1Fallopian Tube Mucinous Adenocarcinoma 1

Interventions

pembrolizumab 95Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 59Cisplatin 56Biopsy 56Nivolumab 51Radiotherapy 47Cyclophosphamide 44Paclitaxel 43Radiation 36durvalumab 33Gemcitabine 31olaparib 30Dexamethasone 30Etoposide 29Doxorubicin 28atezolizumab 26Taxes 25Rituximab 25Docetaxel 25Ipilimumab 24Bevacizumab 24Vincristine 23Lenalidomide 23Pemetrexed 22Cytarabine 22X-Rays 21Radiotherapy, Intensity-Modulated 21Prednisone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Contrast Media × 90 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡